



## Dr. med. Patrik Weder

### Kontakt

Dr. med. Patrik Weder  
Rorschacherstrasse 95  
9007 9007 St. Gallen  
Switzerland

T 071/ 494 11 11  
patrik.weder@kssg.ch

### Bereiche

Medizinische Onkologie und Hämatologie, Brustzentrum St.Gallen

## Publikationen (10)

Huober J, Weder P, Ribí K, Thürlimann B, Thery J, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye A, Müller A, Membrez-Antonioli V, Gerard M, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H, Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group. Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncol* 2023

Schmid S, Zaman K, Weder P, von Moos R, Thürlimann B, Rochlitz C, Pestalozzi B, Pagani O, Oehlschlegel C, Nolè F, Munzone E, Mamot C, Goldhirsch A, Aebi S, Klingbiel D, Ruhstaller T. Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. *BMC cancer* 2019; 19:902.

Zweifel M, Sessa C, Schoenfeld W, Tapia C, Brauchli P, Hawle H, Pilop C, Rothgiesser K, Bigler M, Pagani O, von Moos R, Weder P, Riniker S, Thürlimann B. Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients. *Endocr Connect* 2017; 6:549-556.

Voskens C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Klein C, Keller U, Goldinger S, Loquai C, Robert C, Kaehler K, Berking C, Bergmann T, Bockmeyer C, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Heinzerling L. The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. *PLoS one* 2013; 8:e53745.

Hundsberger T, Brügge D, Putora P, Weder P, Weber J, Plasswilm L. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. *J Neurooncol* 2013; 112:133-9.

Hofer S, Wick W, Zander T, Weder P, Roelcke U, Pichler J, Ochsenbein A, Marosi C, Lemke D, Huber U, Hottinger A, Greil R, Elandt K, Weller M. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. *Acta Oncol* 2011; 50:630-5.

Brügge D, Putora P, Hundsberger T, Weder P, van Leyen K, Plasswilm L (2011). Re-Irradiation with Bevacizumab in Recurrent Malignant Gliomas.

Baumann M, Weder P, Köberle D. Neue Behandlungsoptionen beim metastasierten Kolorektalkarzinom - Bewertung der aktuellen Studienresultate und Konsequenzen. *Schweizer Zeitschrift für Onkologie* 2009:14-19.

Weder P, Anliker M, Itin P, Bargetzi M. Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab. *Dermatology* 2004:3-281.

Weder P, Anliker M, Itin P, Bargetzi M. Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab. *Dermatology (Basel, Switzerland)* 2004; 208:281-3.

## Projekte (13)

**IBCSG 55-17 "Touch" Phase II open-label, multicenter, randomized trial of neo-adjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer**

*Klinische Forschung - 04.12.2018 - 31.12.2021*

*Automatisch geschlossen*

**SAKK 24/14: Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative EGFR positive breast cancer – A multicenter single arm phase II trial**

*Klinische Forschung - 07.11.2016 - 31.05.2023*

*Automatisch geschlossen*

**Eribulin as 1st line treatment in elderly patients ( $\geq 70$  years) with advanced breast cancer: a multicenter phase II trial**

*Klinische Forschung - 11.08.2015 - 30.06.2019*

*Automatisch geschlossen*

**Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum**

*Klinische Forschung - 04.07.2014 - 16.04.2021*

*Automatisch geschlossen*

**A Multicenter Phase III Randomized study with second line chemotherapy plus or minus Bevacizumab in patients with Plati-num sensitive Epithelial ovarian cancer recurrence after a Bevacizumab/chemotherapy first line**

*Klinische Forschung - 27.05.2014 - 27.06.2016*

*Automatisch geschlossen*

**A Phase I and stratified, multicenter Phase II trial of trans-dermal CR1447 (4-OH-testosterone) in endocrine responsive-HER2 negative and triple negative-androgen receptor positive metastatic or locally advanced breast cancer**

*Klinische Forschung - 14.04.2014 - 23.07.2017*

*Automatisch geschlossen*

**A randomized phase II study evaluating different schedules of nab-Paclitaxel in metastatic breast cancer**

*Klinische Forschung - 21.10.2013 - 30.04.2016*

*Abgeschlossen*

**A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer**

*Klinische Forschung - 01.05.2013 - 01.05.2019*

*Automatisch geschlossen*

**SAKK 22/10: A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer**

*Klinische Forschung - 29.04.2013 - 27.06.2015*

*Automatisch geschlossen*

**Avastin plus Radiotherapy in Elderly Patients with Glioblastoma (ARTE) A phase II, randomized, parallel-group, explorative, open labeled multi-center study of bevacizumab (Avastin®) in elderly subjects with newly diagnosed glioblastoma**

*Klinische Forschung - 17.08.2012 - 30.05.2015*

*Abgeschlossen*

**An open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma**

*Klinische Forschung - 05.04.2011 - 30.06.2012*

*Abgeschlossen*

**Assessment of a novel lyophilizable virosome formulation as an adjuvant to the induction of effector cells specific for Melan-A/MART-1 melanoma associated antigen**

*Grundlagenforschung - 01.02.2010 - 31.01.2011*

*Abgeschlossen*

**Ein Phase III Studienprogramm zur Kombination von Bevacizumab, Everolimus (RAD001) oder Lapatinib mit einer neoadjuvanten Chemotherapie bei primärem Mammakarzinom**

*Klinische Forschung - 30.06.2009 - 30.06.2012*

*Abgeschlossen*